New eye injection trial targets rare lymphoma
NCT ID NCT07402876
Summary
This study is testing an experimental injection (ADX-2191) directly into the eye to treat primary vitreoretinal lymphoma, a rare cancer. It will compare two different dosing schedules to see which is safer and more effective at clearing cancer cells. The trial is recruiting about 20 adults who have been diagnosed with this specific eye condition.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY VITREORETINAL LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Bascom Palmer Eye Institute
RECRUITINGMiami, Florida, 33101, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.